Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2016-03-11 07:20 |
BIOPHYTIS receives positive scientific advice on SARCOB BIO101 clinical develop…
|
English | 277.7 KB | ||
| 2016-02-02 07:15 |
BIOPHYTIS annonce la nomination du Dr. Ivana Kim comme Conseil Scientifique
|
French | 116.3 KB | ||
| 2016-02-02 07:15 |
Biophytis Appoints Ivana Kim, M.D., as a Scientific Advisor
|
English | 84.2 KB | ||
| 2016-01-20 18:00 |
BIOPHYTIS : l’américain LifeSci Capital initie la couverture du titre
|
French | 94.5 KB | ||
| 2016-01-07 07:45 |
Biophytis to present at the Biotech Showcase (San Francisco, 11-13 jan.)
|
French | 100.8 KB | ||
| 2016-01-07 07:45 |
Biophytis to present at the Biotech Showcase (San Francisco, 11-13 jan.)
|
English | 81.1 KB | ||
| 2015-12-04 18:31 |
BIOPHYTIS: HALF-YEAR RESULTS FOR 2015
|
English | 141.5 KB | ||
| 2015-12-04 18:30 |
BIOPHYTIS : résultats semestriels au 30 juin 2015
|
French | 147.3 KB | ||
| 2015-12-04 18:01 |
BIOPHYTIS : résultats semestriels au 30 juin 2015
|
French | 147.3 KB | ||
| 2015-12-04 18:01 |
BIOPHYTIS: HALF-YEAR RESULTS FOR 2015
|
English | 141.5 KB | ||
| 2015-12-01 07:20 |
Biophytis Appoints Pierre J. Dilda as Director of Research
|
English | 76.1 KB | ||
| 2015-12-01 07:20 |
BIOPHYTIS annonce la nomination de Pierre J. Dilda au poste de Directeur de la…
|
French | 124.4 KB | ||
| 2015-11-26 07:15 |
BIOPHYTIS présentera le mécanisme d’action de BIO101 lors de la 8ème conférence…
|
French | 139.6 KB | ||
| 2015-11-26 07:15 |
Biophytis to present preclinical proof of concept for Sarcob to treat sarcopeni…
|
French | 80.7 KB | ||
| 2015-11-17 07:59 |
BIOPHYTIS accélère son développement avec le lancement de sa filiale aux Etats-…
|
French | 131.8 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
